Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [ 177 Lu]Lu-prostate-specific membrane antigen (PSMA) therapy.
APA
Abdlkadir AS, Kamal N, et al. (2025). Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.. Clinical nuclear medicine, 50(8), 791-792. https://doi.org/10.1097/RLU.0000000000005792
MLA
Abdlkadir AS, et al.. "Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.." Clinical nuclear medicine, vol. 50, no. 8, 2025, pp. 791-792.
PMID
40524356
Abstract
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [ 177 Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [ 177 Lu]Lu-PSMA therapy, follow-up [ 68 Ga]Ga-PSMA PET/CT revealed progressive skeletal involvement. A bone marrow biopsy confirmed fulminant metastatic castration-resistant prostate cancer infiltration. This case exemplifies PSA pseudoregression, where PSA suggests disease control while imaging shows progression. The patient's condition deteriorated, leading to intensive care admission and death.
MeSH Terms
Humans; Male; Prostatic Neoplasms, Castration-Resistant; Aged; Prostate-Specific Antigen; Lutetium; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Antigens, Surface; Glutamate Carboxypeptidase II; Radioisotopes
같은 제1저자의 인용 많은 논문 (4)
- Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis.
- Beyond [Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
- PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review.
- Intense fibroblast activation protein inhibitor localization around the site of embolized gastroduodenal artery in a patient with metachronous pancreatic adenocarcinoma: A potential pitfall in positron imaging.